#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
medScope.pro / Journals / Diabetes and obesity / 2020 - 39

The benefit of insulin glargine 300 U/ml for specific groups of patients in the context of available data

Czech version

Authors: Peter Novodvorský 1,2
Authors‘ workplace: metabolické centrum s. r. o., Trenčín 1;  Department of Oncology & Metabolism, Medical School, University of Sheffield, United Kingdom 2
Published in: Diab Obez 2020; 20(39): 28-34
Category: Reviews

Overview

Potreba iniciácie terapie inzulínom v určitej fáze diabetu 2. typu (DM2T) vyplýva z patofyziológie tohoto ochorenia. Otázka správnej indikácie a načasovania inzulínoterapie pri DM2T však zostáva pomerne kontroverznou témou. Táto práca predstavuje hlavné výsledky štúdie BRIGHT a následných subanalýz BRIGHT Renal a BRIGHT Elderly a analyzuje ich význam pre správnu voľbu inzulínového preparátu pri iniciácii inzulínoterapie u pacientov s DM2T s ohľadom na ich vek a pridružené komorbidity, akými sú napr. chronická obličková choroba.

Keywords:

basal insulin – chronic kidney disease – diabetic nephropathy – elderly people with diabetes – glargine 300 U/ml – hypoglycaemia – insulin degludec – nocturnal hypoglycaemia – type 2 diabetes (DM2T)

Sources
  1. Lean ME, Leslie WS, Barnes AC et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391(10120): 541–551. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(17)33102–1>.
  2. IDF Diabetes Atlas. 9th ed. International Diabetes Federation: Brussells, Belgium 2019. Dostupné z WWW: <http://www.diabetesatlas.org>.
  3. Home P, Riddle M, Cefalu WT et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 2014; 37(6): 1499–1508. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–2743>.
  4. Davies MJ, D’Alessio DA, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669–2701. Dostupné z DOI: <http://dx.doi.org/10.2337/dci18–0033>.
  5. Iqbal A, Novodvorsky P, Heller SR. Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians. Diabetes Metab J 2018; 42(1): 3–18. Dostupné z DOI: <http://dx.doi.org/10.4093/dmj.2018.42.1.3> Erratum in Corrigendum: Table and Text Correction. Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians. [Diabetes Metab J 2018].
  6. Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab 2017; 19(1): 3–12. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12782>.
  7. Ratner RE, Gough SC, Mathieu C et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15(2): 175–184. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12032>.
  8. Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015; 17(9): 859–867. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12485>.
  9. Lane W, Bailey TS, Gerety G et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients with Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA 2017; 318(1): 33–44. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2017.7115>.
  10. Wysham C, Bhargava A, Chaykin L et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients with Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA 2017; 318(1): 45–56. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2017.7117>.
  11. Rosenstock J, Cheng A, Ritzel R et al. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care 2018; 41(10): 2147–2154. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18–0559>.
  12. Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol 2017; 13(7): 385–399. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2017.39>.
  13. Kawaguchi Y, Sawa J, Hamai C et al. Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec. Diabetes Ther 2019; 10(4): 1535–1541. Dostupné z DOI: <http://dx.10.1007/s13300–019–0654-y>.
  14. Mauricio D, Meneghini L, Seufert J et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab 2017; 19(8): 1155–1164. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12927>.
  15. Frier BM, Landgraf W, Zhang M et al. Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus. Diabetes Obes Metab 2018; 20(12): 2894–2898. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13450>.
  16. Harris S, Berard L, Westerbacka J et al. Early hypoglycemia after initiation of second-generation basal insulin (BI) analogs: patient characteristics and clinical outcomes. ADA 79th Scientific Sessions; 7–11th June 2019; San Francisco, USA. Diabetes 2019; 68(Suppl 1): 1095-P. Dostupné z DOI: < https://doi.org/10.2337/db19–1095-P >.
  17. Bailey RA, Wang Y, Zhu V et al. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes 2014; 7: 415. Dostupné z DOI: <http://dx.doi.org/10.1186/1756–0500–7-415>.
  18. Wu B, Bell K, Stanford A et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007–2012. BMJ Open Diabetes Res Care 2016; 4(1): e000154. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjdrc-2015–000154>.
  19. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351(13): 1285–1295. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa041365>.
  20. Alsahli M, Gerich JE. Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc 2014; 89(11): 1564–1571. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mayocp.2014.07.013>.
  21. Sullivan SD, Bailey TS, Roussel R et al. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes Obes Metab 2018; 20(9): 2148–2158. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13345>.
  22. Haluzík M, Phillis-Tsimikas A, Bosnyak Z et al. Differences in HbA1c lowering effect and hypoglycemia risk between Gla 300 and IDeg according to renal function in the BRIGHT Trial. ADA 79th Scientific Sessions; 7–11th June 2019; San Francisco, USA. Diabetes 2019; 68(Suppl 1): 146-OR. Dostupné z DOI: < https://doi.org/10.2337/db19–146-OR>.
  23. Charbonnel B, Vanita RA, Westerbacka J et al. Differences in HbA1c reduction between insulin glargine 300 U/mL (Gla-300) and insulin degludec100 U/mL (IDeg-100) in adults ≥70 years of age with T2DM in the BRIGHT trial. ADA 79th Scientific Sessions; 7–11th June 2019; San Francisco, USA. Diabetes 2019; 68(Suppl 1): 131-LB. Dostupné z DOI: <https://doi.org/10.2337/db19–131-LB>.
Labels
Diabetology Obesitology
Comparison of the most recent guidelines for hyperglycemia management in patients with type 2 diabetes mellitus
Concentrations of fT3 in child patients with obesity
Non-alcoholic fatty liver disease from the point of view of diabetologist
Diabetes mellitus and liver diseases
Management of antidiabetic treatment in an elderly fragile patient with diabetes mellitus
Peroral antidiabetics and thyroid diseases
COVID-19: the topic of the day
Article was published in

Diabetes and obesity

Issue 39
2020 Issue 39
Download issue PDF
Popular this week
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#